Entity

Time filter

Source Type

Cambridge, MA, United States

This invention relates to a transdermal delivery system for treating skin related diseases employing papilloma-derived protein nanoparticles to deliver drugs to the keratinocytes and basal membrane cells for the treatment of alopecia. The current invention presents an effective method for delivering small molecule nucleic acids to the epidermal cells.


This invention relates to a transdermal delivery system for treating skin related diseases employing protein nanoparticles to deliver drugs to the keratinocytes and basal membrane cells for the treatment of Psoriasis. The current invention presents an effective method for delivering small molecule nucleic acids to the epidermal cells.


The invention is directed to novel compositions and methods utilizing virion derived protein nanoparticles for delivery of medical imaging agents and therapeutic agents for the diagnosis and treatment of malignant and systemic diseases. The nanoparticles of the present invention are designed to deliver radioactive isotopes suitable for imaging a tumor and its metastases. Additionally, the nanoparticles may deliver a radioisotope that is suitable for treating a tumor and its metastases by alpha, beta or gamma radiation. Alternatively, the virion derived nanoparticles may deliver a treatment agent for cancer or a combination of a radioisotope and a cancer treatment agent. Additionally the virion derived nanoparticle may include delivery of a drug that enhances the immune systems recognition of the tumor.


The invention is directed to novel compositions and methods utilizing virion derived protein nanoparticles for delivery of medical imaging agents and therapeutic agents for the diagnosis and treatment of malignant and systemic diseases.


News Article | March 5, 2015
Site: blogs.wsj.com

When cancer forms in the eye the goal of treatment is to save the patient’s life first and preserve vision second. Investors are betting Aura Biosciences Inc. can do both. Tumors can form in the eye or spread there from another location, such as the breasts or lungs. The most common primary eye tumors in adults are melanoma and lymphoma, according to the American Cancer Society. In February Oliver Sacks, the author and New York University School of Medicine professor, said in a New York Times article that the ocular melanoma he was diagnosed with nine years ago had spread to his liver. The radiation and laser treatment he previously received ultimately left him blind in the eye, he wrote. Aura precisely targets its treatment so that normal cells are unharmed. This could enable it to treat ocular tumors while preserving vision. With $21 million in Series B venture financing, it plans to test this technology in clinical trials beginning later this year. Aura’s product is a viral nanoparticle coupled with a tumor-killing drug. Once injected into the eye, the nanoparticle binds to the tumor and causes the drug to be taken up by the cancer. Then a laser is shone into the eye to activate the drug, which disrupts the tumor membrane and creates toxic free oxygen radicals. The approach could work in many types of cancer, but Aura elected to concentrate on rare tumors of the eye initially, according founder and Chief Executive Elisabet de los Pinos. Serving small patient populations could enable Aura to take its product to market independently. The Cambridge, Mass., company has yet to reveal the disease it will target in its initial clinical studies. Ophthalmologists are accustomed to injecting drugs into the eye because of the success of products such as Lucentis, a treatment for diseases such as the wet form of age-related macular degeneration sold by Roche Holding and Novartis AG. In addition, the laser in Aura’s treatment is the same as the one used in Visudyne, a light-activated drug from Bausch & Lomb Inc. that is also used in macular degeneration patients, according to Dr. de los Pinos. Aura is one of many companies attracting venture funding to develop therapies for eye diseases. Venture firms, capitalizing on new approaches to treating blinding illnesses, invested $1.3 billion in eye treatments last year, up 58% from 2013, according to Dow Jones VentureSource. Advent Life Sciences led this round for Aura, which also included Alexandria Venture Investments, Chiesi Ventures, LI-COR Biosciences and Ysios Capital. Former Genzyme Corp. CEO Henri Termeer also participated. Dale Pfost, a general partner at Advent Life Sciences, Art Pappas, managing partner of Pappas Ventures, and Joël Jean-Mairet, managing partner at Ysios Capital, are joining Aura’s board. Current board member Alan Walts, former head of Genzyme Ventures, will become executive chairman.

Discover hidden collaborations